You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Illumina Ventures led the round for the Santa Clara, California-based firm, which is developing applications for its optical detection technology.
Healthcare providers need multiplexed tests that can differentiate the flu from the coronavirus so they can treat patients quickly and appropriately.
The test was already authorized for use in Canada and South Korea. Seegene has sold more than 10 million of the assay in more than 60 countries.
Seegene said Monday that the Health Canada approval will enable hospitals and licensed labs there to run the assay immediately for high-volume testing.
CNN describes how Seegene in South Korea quickly developed and manufactured a test for SARS-CoV-2.
The single-tube real-time PCR-based test has also received CE marking, according to Seegene, and is now commercially available.
Invitae said this week that it completed its acquisition of Singular Bio on June 19.
QuantuMDx and Molbio Diagnostics said this week they have signed a memorandum of understanding to work jointly in infectious disease diagnostics.
Through the joint collaboration, Seegene plans to accelerate development of its random access system on Hamilton's automated liquid handling platforms.
SARS-CoV-2 vaccine developers are evaluating further vaccine doses as well as modified doses to keep up with new viral variants, according to CNN.
The New York Times reports that a new viral variant of concern has been identified in New York City.
In Nature this week: spatiotemporally resolved map of the human cell cycle, folding single-cell RNA sequencing into cancer drug studies, and more.
According to BBC News, the global vaccine-sharing initiative has sent its first shipment, which arrived in Ghana this week.